Why Moderna's Next Step For Its Coronavirus Vaccine is Crucial

Moderna (NASDAQ:MRNA) had good news for investors during its earnings report this week: The company received a nod from the U.S. Food and Drug Administration to begin phase 2 trials for its coronavirus vaccine. And there's more. Moderna also said it aims to start phase 3 testing early this summer -- that's sooner than Moderna's original goal of this fall.